News & Events about Cymabay Therapeutics Inc.
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 ...
Ticker Report
2 months ago
CymaBay Therapeutics (NASDAQ:CBAY Get Rating) had its price target lifted by HC Wainwright from $10.00 to $12.00 in a research note published on Friday, The Fly reports. Other equities research analysts also recently issued research reports about the company. Raymond James increased their ...
Ticker Report
3 months ago
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) Equities research analysts at Oppenheimer boosted their FY2024 earnings per share estimates for CymaBay Therapeutics in a research report issued to clients and investors on Monday, March 6th. Oppenheimer analyst J. Olson now expects...
Globe Newswire
3 months ago
NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd...
Globe Newswire
4 months ago
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities ...